Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to test the safety of the study drug 2141-V11 in people whose NMIBC did not respond to standard treatment, and who will not have the standard surgical procedure to remove the bladder. The researchers will test different doses of 2141-V11 to see which dose is safest in people. The researchers will also do tests to see how the body absorbs, distributes, and gets rid of 2141-V11. This study is one of the first to test 2141-V11 in people, and the first to test 2141-V11 delivered through a catheter into the bladder.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05126472
Study type Interventional
Source Memorial Sloan Kettering Cancer Center
Contact Bernard Bochner, MD
Phone 646-422-4387
Email [email protected]
Status Recruiting
Phase Phase 1
Start date November 8, 2021
Completion date November 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05014139 - A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) Phase 1
Recruiting NCT04943094 - Clinical and Functional Consequences of Photodynamic Diagnosis (PDD) and Intravesical Instillation Therapy
Completed NCT02969109 - Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer
Completed NCT01458847 - Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer Phase 1
Recruiting NCT03914794 - A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors Phase 2
Not yet recruiting NCT04736394 - A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients Phase 3
Recruiting NCT04644835 - Low Energy Shock Wave Therapy and Non-Muscle Invasive Bladder Cancer N/A
Recruiting NCT05085977 - Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) Phase 1
Recruiting NCT04100733 - Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer Monitor Phase 3
Recruiting NCT03560479 - A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer Phase 1/Phase 2
Terminated NCT01310803 - Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder Phase 3
Active, not recruiting NCT03081858 - Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer Phase 1/Phase 2
Completed NCT04498702 - Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy Phase 2
Active, not recruiting NCT04490993 - Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients Phase 3
Recruiting NCT04859751 - Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer Phase 3
Not yet recruiting NCT05085990 - Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer Phase 1
Recruiting NCT03933826 - CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer
Recruiting NCT02138734 - A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT04375813 - Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention Phase 2
Completed NCT02316171 - CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON) Phase 1